Previous studies reported that the consumption of microencapsulated sodium butyrate reduced signs of clinical severity of symptomatic uncomplicated diverticular disease, irritable bowel syndrome or inflammatory bowel disease [34,35,36,37,74], improved insulin sensitivity and reduced blood pressure [38,39] in human patients. Here, INS is linked to diverticular disease.